Illumina (ILMN) News Today

Illumina, Inc. (NASDAQ: ILMN) shares have decreased after an initially positive reaction to the company’s second-quarter results, as investors weighed strong earnings and upgraded guidance against ongoing China weakness and an unchanged margin outlook.

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.